METPRC Mutations in the Ron Receptor Result in Upregulation of Tyrosine Kinase Activity and Acquisition of Oncogenic Potential

Journal of Cellular Physiology

Volumn 181, Issue 3, 1999, Pages 507-514

  Williams, Tracy A ^a   Longati, Paola ^a   Pugliese, Luisa ^a   Gual, Philippe ^a   Bardelli, Alberto ^a   Michieli, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ANALYSIS; GENE MUTATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS;

3T3 CELLS; AMINO ACID SUBSTITUTION; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; MICE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; ONCOGENES; PHOSPHORYLATION; POINT MUTATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; TYROSINE; UP-REGULATION;

ANIMALIA;

EID: 0032693771     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q     Document Type: Article

References (32)

1. Abagyan R, Totrov M. 1994. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 235:983-1002.
2. Bardelli A, Longati P, Gramaglia D, Stella MC, Comoglio PM. 1997. Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 15:3103-3111.
3. Boccaccio C, Ando' M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391:285-288.
4. Collesi C, Santoro MM, Gaudino G, Comoglio PM. 1996. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16:5518-5526.
5. Comoglio PM, Boccaccio C. 1996. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes to Cells 1:347-354.
6. Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA, Comoglio PM. 1992. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7:2549-2553.
7. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, Sismondi P, Comoglio PM. 1994. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 58:658-662.
8. Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM. 1995. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene 11:2627-2637.
9. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM. 1994. Ron is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13:3524-3532.
10. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. 1989. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339:155-156.
11. Go N, Scheraga HA. 1970. Ring closure and local conformational deformations of chain molecules. Macromolecules 3:178-187.
12. Hanks S, Quinn AM. 1991. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 200:38-62.
13. Heldin CH. 1995. Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.
14. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JWM, Kristian H, van Amstel P, Romeo G, Lips CJM, Buys CHCM. 1994. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
15. Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16:5572-5581.
16. Hubbard SR, Wei L, Ellis L, Hendrickson WA. 1994. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372:746-754.
17. Iwama A, Yamaguchi N, Suda T. 1996. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBOJ 15:5866-5875.
18. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. 1997. Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94:11445-11450.
19. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. 1994. Tyrosines 1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9:49-57.
20. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismond P, Comoglio PM. 1998. Overexpression of the RON gene in human breast carcinoma. Oncogene 16:2927-2933.
21. Medico E, Mongiovi AM, Huff J, Jelinek M-A, Follenzi A, Gaudino G, Parsons JT, Comoglio PM. 1996. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 7:495-504.
22. Michieli P, Li W, Lorenzi MV, Miki T, Zakut R, Givol D, Pierce JH. 1996. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells. Oncogene 12:775-784.
23. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560- 10564.
24. Nemethy G, Gibson KD, Palmer KA, Yoon CN, Paterlini G, Zagari A, Rumsey S, Scheraga HA. 1992. Energy parameters in polypeptides. Improved geometric parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides. J Phys Chem 96:6472-6484.
25. Nguyen L, Holgado-Madruga M, Maroun C, Fixman ED, Kamikura D, Fournier T, Charest A, Tremblay ML, Wong AJ, Park M. 1997. Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem 272:20811- 20819.
26. Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A. 1996. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93:14665-14669.
27. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. 1994. A multifunctional docking site mediates signalling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261-271.
28. Sali A, Blundell T. 1993. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
29. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. 1996. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol 16:7072-7083.
30. Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G. 1998. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17:741-749.
31. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamar A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui L-C, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
32. Zarnegar R, Michalopoulos GK. 1995. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 129:1177-1180.